Elicit
NativeAI NativePrivateUpdated November 15, 2026AI research assistant helping academics synthesize evidence from scientific papers, automating literature review and systematic research workflows...
Try it free →- Website
- elicit.com
- Founded
- 2021
- CEO
- Andreas Stuhlmüller
- HQ
- Oakland, United States
- Stage
- Series A
- Revenue
- Not disclosed
- Total Funding
- $31M
- Employees
- 11-50
Executive Summary
Updated Nov 12, 2026
What they do
- AI research assistant that searches 138M+ papers and 545K clinical trials
- Automates systematic reviews: search, screening, data extraction and PRISMA-aligned reporting
- Offers Research Agent, cited Reports, recurring Routines, an API and an MCP server
Why it matters
- Cuts literature-review time sharply; Oxford PharmaGenesis reviewed 500 papers in a week
- Built around transparent, sentence-level citations, giving evidence-heavy teams an audit trail
- API and MCP connectors put grounded evidence search inside Claude, ChatGPT and internal agents
Best fit
- Pharma, HEOR and medical communications teams running evidence synthesis at scale
- Government, academic and nonprofit research groups doing systematic or rapid reviews
- R&D teams building research agents that need programmatic access to scientific literature
Watch-outs
- Small vendor of about 60 staff with roughly $31M raised in total
- Covers academic sources only; no internal documents, patents or broad web content
- Shared monthly usage pools and per-review paper caps can limit heavy workloads
Products & Offerings
Elicit Systematic Review
Guided end-to-end systematic review workflow covering search, screening, full-text extraction and reporting aligned with PRISMA 2020.
Elicit Research Agent
Agentic research workspace for exploring a topic, mapping a research landscape or competitors, and answering questions with cited sources.
Elicit Reports
Automated, fully cited research overviews generated from hundreds of papers in response to a single research question.
Elicit API and MCP Server
Programmatic Search, Reports and Systematic Review endpoints, also available as a Claude connector or ChatGPT plugin over MCP.
Elicit Routines
Recurring agent tasks that watch for new evidence, update existing research work and report changes for review.
Updated Nov 12, 2026
Elicit is one of the most credible specialist tools for AI-assisted evidence synthesis. It holds SOC 2 Type II, has a systematic review workflow aligned with PRISMA 2020, and names users such as NIH, the CDC, Johnson & Johnson and Takeda. Pharma, HEOR and research organizations should run a structured pilot against their own validated reviews, checking recall and extraction accuracy themselves. Because the company is small and Series A-funded, ask about data portability, usage limits and long-term support before committing.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 14, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 15, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 9, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Nov 15, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | Research agents (estimate) |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 15, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Elicit's Bluescore of 37.8 rests most on Product Depth (4.9, 53rd percentile) and Talent & Research (4.0, 50th percentile). Its weakest area is Investment Momentum (1.5, 5th percentile).
In plain English
Elicit has a Bluescore of 37.8 out of 100 and ranks #202 of 247, down 4 places since yesterday. Its strongest contributions come from Product Depth, which scores 4.9 of 10 and adds 10.4 of 21 points, and Customer Adoption, which scores 5.2 of 10 and adds 6.8 of 13 points, while Investment Momentum scores just 1.5 of 10 and sits at the 5th percentile. The biggest drag is Business Model & Revenue, which carries a 21% weight but scores only 3.0 of 10, adds 6.2 of 21 points, and has 14.8 points still left, so improving it would move the score the most.
Written by AI from the scores below and checked against them; updated nightly.
Traction Signals
Last Round
Series A
Risks
Updated Nov 12, 2026